Association of the Expression Level of miR-16 with Prognosis of Solid Cancer Patients: A Meta-Analysis and Bioinformatic Analysis

Table 2

Pooled and subgroup analyses stratified by potential modifying factors on the association between miR-16 and overall survival (OS) of solid cancer patients.

Subgroup	No. of studies	HR (95% CI)	value	(%)	for heterogeneity	in metaregression
Overall	13	1.47 (1.13-1.91)	0.004	84.0%	≤0.001
Publication year						0.672
>2014	8	1.38 (0.92-2.06)	0.117	81.9%	≤0.001
≤2014	5	1.63 (1.04-2.57)	0.034	88.3%	≤0.001
Cancer site						0.360
Digestive system	7	1.32 (0.72-2.39)	0.368	85.7%	≤0.001
Reproductive system	3	1.24 (1.06-1.45)	0.008	33.3%	0.224
Other	3	2.07 (1.38-3.10)	≤0.001	63.5%	0.064
Region						0.280
Asia	9	1.62 (1.15-2.29)	0.006	71.7%	≤0.001
Europe	1	0.43 (0.23-0.81)	0.009	—	—
America	3	1.59 (1.00-2.53)	0.049	92.8%	≤0.001
Sample size						0.138
<100	2	0.55 (0.33-0.93)	0.025	0.0%	0.403
100-199	8	1.63 (1.15-2.30)	0.006	82.8%	≤0.001
≥200	3	1.77 (1.17-2.67)	0.007	78.2%	0.010
Quality score						0.897
<15	6	1.44 (0.92-2.25)	0.109	80.2%	≤0.001
≥15	7	1.50 (1.03-2.19)	0.036	86.9%	≤0.001
Statistical method						0.312
Cox mode	10	1.64 (1.17-2.30)	0.004	85.9%	≤0.001
Log-rank	3	1.09 (0.64-1.85)	0.747	81.9%	0.004
Biosample						0.986
Tissue	9	1.46 (1.11-1.93)	0.008	80.0%	≤0.001
Serum or plasma	4	1.46 (0.71-2.99)	0.300	87.7%	≤0.001

HR: hazard ratio; CI: confidence interval.